An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.

Abstract

Atypical hemolytic uremic syndrome is a rare thrombotic microangiopathy caused by chronic defective regulation of the complement activation. This activation results in systemic endothelial damage leading to renal failure. Eculizumab, an anti-C5 antibody, is effective in limiting complement activation in patients with aHUS and has recently came out as a therapeutic option for aHUS. Here we present a case showing that first-line eculizumab treatment successfully prevents the induction of the terminal complement cascade and blocked the progression of thrombotic microangiopathy in aHUS.

• Authors: Nilay Sengul Samanci, Mesut Ayer, Abdulkadir Ergen, Savas Ozturk
• Journal: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis (Transfus Apher Sci) Vol. 52 Issue 3 Pg. 314-6 (Jun 2015) ISSN: 1473-0502 [Print] England
• PMID: 25634788 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2015 Elsevier Ltd. All rights reserved.

Chemical References

• Antibodies, Monoclonal, Humanized
• eculizumab

Topics

• Antibodies, Monoclonal, Humanized (therapeutic use)
• Atypical Hemolytic Uremic Syndrome (drug therapy, therapy)
• Complement Activation
• Disease Progression
• Humans
• Kidney (pathology)
• Male
• Middle Aged
• Plasma Exchange (methods)
• Renal Dialysis
• Thrombotic Microangiopathies (immunology)
• Treatment Outcome